Vaginal microbicides: What does the future hold?

Contemporary Ob/Gyn

Volumn 53, Issue SPEC. ISS., 2008, Pages

  Cates Jr , Willard ^a   Rosenberg, Zeda ^b  

^a FAMILY HEALTH INTERNATIONAL   (United States)

^b INTERNATIONAL PARTNERSHIP FOR MICROBICIDES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 42349109469     PISSN: 00903159     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (19)

1. Balzarini J, Van Damme L. Intravaginal and intrarectal microbicides to prevent HIV infection. CMAJ. 2005;172:461-464.
2. Hillier SL, Moench T, Shattock R, et al. In vitro and in vivo: the story of nonoxynol 9. J Acquir Immune Defic Syndr. 2005;39:1-8.
3. Cates W Jr, Stewart FH, Trussell J. Commentary: the quest for women's prophylactic methods - hopes vs science. Am J Public Health. 1992;82:1479-1482.
4. Richardson BA, Lavreys L, Martin HL Jr, et al. Evaluation of low-dose nonoxynol-9 gel for the prevention of sexually transmitted diseases: a randomized clinical trial. Sex Transm Dis. 2001;28:394-400.
5. Roddy RE, Zekeng L, Ryan KA, et al. A controlled trial of nonoxynol-9 film to reduce male-to-female transmission of sexually transmitted diseases. N Engl J Med. 1998;339:504-510.
6. Roddy RE, Zekeng L, Ryan KA, et al. Effect of nonoxynol-9 gel on urogenital gonorrhea and chlamydial infection. JAMA. 2002;287:1117-1122.
7. Van Damme L, Ramjee G, Alary M, et al. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised, controlled trial. Lancet. 2002;360:971-977.
8. Richardson BA. Nonoxynol-9 as a vaginal microbicide for prevention of sexually transmitted infections: it's time to move on. JAMA. 2002;287:1171-1172.
9. Van Damme L. Update on CONRAD Cellulose Sulfate trial. Abstract from IAS Meeting, Sydney, Australia. July, 2007.
10. Scholand SJ, DeSimone JA, Pomerantz RJ. Anti-HIV-1 microbicides - 'chemical condoms' designed to limit the scourge of the HIV-1 pandemic. Curr Pharm Des. 2005;11:3747-3756.
11. Alliance for Microbicide Development. Microbicide Candidates in Clinical Development. The Microbicide Quarterly. 2006;4(4):20. http://www.microbicide.org/microbicideinfo/reference/TMQ.Oct-Dec2006.FINAL.pdf.
12. Motakis D, Parniak MA. A tight-binding mode of inhibition is essential for anti-human immunodeficiency virus type 1 virucidal activity of nonnucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother. 2002;46:1851-1856.
13. Fernandez-Romero JA, Thorn M, Turville SG, et al. Carrageenan/MIV-150 (PC-815), a combination microbicide. Sex Transm Dis. 2007;34:9-14.
14. Nuttall J, Romano J, Douville K, et al. The future of HIV prevention: prospects for an effective anti-HIV microbicide. Infect Dis Clin North Am. 2007;21:219-239.
15. Martinez J, Coplan P, Wainberg MA. Is HIV drug resistance a limiting factor in the development of anti-HIV NNRTI and NRTI-based vaginal microbicide strategies? Antiviral Res. 2006;71:343-50.
16. Romano J, Coplan P, Mitchnick M, et al. Characterization of in vitro release and in vivo delivery of TMC120 with an intravaginal ring: Implications for microbicide delivery [abstract WEAA0503]. XVI International AIDS Conference, Toronto, August 2006. http://www.natap.org/2006/IAS/IAS_65.htm. Accessed March 25, 2008.
17. Skoler S, Peterson L, Cates W. Our current microbicide trials: Lessons learned and to be learned. Alliance for Microbicide Development. The Microbicide Quarterly. 2006;4(1):20. http://www.popcouncil.org/pdfs/TMQ_4_1. pdf. Accessed March 25, 2008.
18. Raymond EG, Taylor D, Cates W Jr, et al. Pregnancy in effectiveness trials of HIV prevention agents. Sex Transm Dis. 2007;34:1035-1039.
19. Fleming TR, Richardson BA. Some design issues in trials of microbicides for the prevention of HIV infection. J Infect Dis. 2004;190:666-674.